NEAT1 lncRNA overexpression results in short‐term progression and poor treatment outcome in childhood B‐ ALL
British Journal of Haematology · 2025
DOI: 10.1111/bjh.70127 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Marieta Xagorari und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Biochemistry-Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University …. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Gene Expression Regulation, Leukemic. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Childhood acute lymphoblastic leukaemia (chALL) remains the most prevalent malignancy in children and adolescents. Improving risk stratification and providing personalized prognosis and treatment remain major clinical challenges. Herein, we analysed the clinical utility of NEAT1 lncRNA for the prognosis and prediction of treatment outcome of childhood B‐cell precursor ALL (chB‐ALL). NEAT1_1 isoform was quantified in bone marrow samples of chB‐ALL patients at diagnosis ( n = 160) and at the end of induction ( n = 108) of ALL‐BFM protocol, and in age‐matched healthy children ( n = 68). Relapse and death served as clinical end‐points for survival analysis. Bootstrap analysis was performed for internal validation and decision curve analysis assessed the clinical net benefit for chB‐ALL prognosis. Our analysis showed that chB‐ALL patients with NEAT1 overexpression at diagnosis are at significantly higher risk for progression (HR = 2.957, 95% CI: 1.122–7.790, p = 0.011) and worse survival (HR = 5.832, 95% CI: 1.259–27.01, p = 0.012), independently of clinicopathological and treatment data. Moreover, NEAT1‐fitted multivariate models resulted in improved risk stratification compared to the conventional disease markers of white blood cells, bone marrow response and minimal residual disease, while decision curve analysis highlighted the superior clinical net benefit for chB‐ALL prognosis. In conclusion, NEAT1 overexpression constitutes a powerful, independent predictor of poor treatment outcomes and disease progression of chB‐ALL, providing refined stratification of patient's risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Clinical Biochemistry-Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, 'P. & A. Kyriakou' Children's Hospital, Athens, Greece.
- Department of Pediatric Oncology, 'P. & A. Kyriakou' Children's Hospital, Athens, Greece.
- Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, 'P. & A. Kyriakou' Children's Hospital, Athens, Greece.
- Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece.
ORCID-Profile: Andreas Scorilas, Margaritis Avgeris
Zitieren
APA
Xagorari, M., Marmarinos, A., Doganis, D., Nikita, M., Magkou, E., Sfetsiori, A. E., Baka, M., Kossiva, L., Pasparaki, S., Soldatou, A., Tsolia, M., Scorilas, A., Gourgiotis, D., & Avgeris, M. (2025). NEAT1 lncRNA overexpression results in short‐term progression and poor treatment outcome in childhood B‐ ALL. British Journal of Haematology. https://doi.org/10.1111/bjh.70127
Vancouver
Xagorari M, Marmarinos A, Doganis D, Nikita M, Magkou E, Sfetsiori AE, et al. NEAT1 lncRNA overexpression results in short‐term progression and poor treatment outcome in childhood B‐ ALL. British Journal of Haematology. 2025. doi:10.1111/bjh.70127
BibTeX
@article{Xagorari2025,
author = {Xagorari, Marieta and Marmarinos, Antonios and Doganis, Dimitrios and Nikita, Maria and Magkou, Evgenia and Sfetsiori, Angeliki-Eleni and Baka, Margarita and Kossiva, Lydia and Pasparaki, Sofia and Soldatou, Alexandra and Tsolia, Maria and Scorilas, Andreas and Gourgiotis, Dimitrios and Avgeris, Margaritis},
title = {NEAT1 lncRNA overexpression results in short‐term progression and poor treatment outcome in childhood B‐ ALL},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.70127}
}
EUVIMED